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Abstract
Pathological progression of stroke in the peripheral and central nervous systems (PNS
and CNS) is characterized by multiple converging signalling pathways that exacerbate
neuroinflammation-mediated secondary cell death. This creates a need for a novel
type of immunotherapy capable of simultaneously lowering the synergistic inflammatory responses in the PNS and CNS, specifically the spleen and brain. Previously, we
demonstrated that partial major histocompatibility complex (MHC) class II constructs
can be administered subcutaneously to promote histological and behavioural effects
that alleviate common symptoms found in a murine model of transient stroke. This
MHC class II manipulates T cell cytokine expression in both PNS and CNS, resulting in
dampened inflammation. In our long-standing efforts towards translational research,
we recently demonstrated that a potent next generation mouse-based partial MHC
class II construct named DRmQ (DRa1L50Q-mMOG-35-55) similarly induces neuroprotection in stroke rats, replicating the therapeutic effects of the human homolog
as DRhQ (DRa1L50Q-human (h)MOG-35-55) in stroke mice. Our preclinical studies
showed that DRmQ reduces motor deficits, infarct volume and peri-infarct cell loss
by targeting inflammation in this second species. Moreover, we provided mechanistic support in both animal studies that partial MHC class II constructs effectively
modulate the spleen, an organ which plays a critical role in modulating secondary
cell death. Together, these preclinical studies satisfy testing the constructs in two
stroke models, which is a major criterion of the Stroke Therapy Academic Industry
Roundtable (STAIR) criteria and a key step in effectively translating this drug to the
clinic. Additional translational studies, including dose-response and larger animal
models may be warranted to bring MHC class II constructs closer to the clinic.
KEYWORDS

cerebral ischaemia, cytokines, immune response, major histocompatibility complex class II,
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1 | I NTRO D U C TI O N

translational research challenges that warrant further investigations
to bring partial MHC II constructs to clinical applications are also

Cerebral ischaemia is a leading cause of death in the world and

presented. The ultimate goal of this review paper is to offer a critical

remains the primary cause of long-term disability in the United

assessment of existing discovery- and mechanism-based data and

States.1-3 Ischaemic stroke accounts for 87% of stroke incidents,

identify gaps in knowledge towards the advancement of safe and

with nearly one-third of the patients succumbing to death, while

effective partial MHC II constructs as stroke therapeutics.

another 20% to 30% becoming severely and permanently disabled.
1-3

Ischaemic stroke is characterized by an acute primary cell death

response, followed by secondary cell death in the subacute and
1-3

chronic phase.

Several signalling pathways accompany secondary

cell death in stroke, including exacerbated inflammation in both the

2 | PA RTI A L M H C I I CO N S TRU C T S
S EQ U E S TE R N EU RO I N FL A M M ATI O N I N
ANIMAL MODELS OF CNS DISORDERS

central and peripheral nervous system (CNS and PNS). This inflammation is considered a primary culprit in secondary cell death.4

To address this gap in inflammation-targeted treatment, a series of

Effective treatment of ischaemic stroke relies on a narrow time-

laboratory investigations examined the efficacy of partial major histo-

line that disqualifies more than 90% of patients.5-7 Patients face a

compatibility complex (MHC) class II construct DRa1-mMOG-35-55

limited number of therapeutic options: tissue plasminogen activator

(DRa1 domain covalently linked to mouse (m)MOG-35-55 peptide),

(tPA), mechanical reperfusion, stroke unit care and rehabilitation.5-8

which is an immune-targeted therapeutic that significantly antago-

Furthermore, for tPA, the current standard of care, treatment of

nizes the acute recruitment and activation of brain-infiltrating T cells

ischaemic stroke must commence within 4.5 hours.9 Therefore,

caused by CNS insults.11,20 These partial MHC class II constructs

novel approaches that extend the therapeutic window of tPA are

successfully reduced inflammation, infarct volume and cognitive

warranted.8-10 To this end, the subacute and chronic evolution of

deficits in animal models of four separate neurodegenerative and

inflammation presents an opportunity to develop innovative stroke

neuroinflammatory CNS conditions, including experimental autoim-

therapies.8,11

mune encephalomyelitis (EAE), methamphetamine addiction, trau-

Perturbed immune response represents a key underlying pa-

matic brain injury and ischaemic injury.11

thology of many neurovascular, autoimmune and traumatic injuries

Encouraged by positive efficacy readouts in animal models of neu-

of the CNS including stroke. Secondary cell death involves multiple

rological disorders, a second more potent generation of partial MHC

pathways, but a major process entails a feedback loop of neuroinflammation, resulting in hypoxic tissues, vascular damage and bloodbrain barrier (BBB) leakage, expanding outward from the region of

mMOG-35-55) for preclinical testing. 21 DRa1L50Q-mMOG-35-55 is

The aberrant immune response-associated secondary

effective in treating EAE in mice, a model of multiple sclerosis. 21 In

cell death in stroke manifests as an initial acute inflammatory re-

parallel, the DRmQ precursor, DRa1-mMOG-35-55, reduces stroke

sponse characterized by influx across the BBB of activated mononu-

symptoms in middle cerebral artery occlusion (MCAo) stroke mice22

clear cells subsequently evolving into chronic and often progressive

and in distal middle artery occlusion dMCAO stroke mice by shifting

deterioration of the neurovascular unit. Neutrophils stand as key

microglia/macrophages towards the antiinflammatory M2 pheno-

cellular mediators of the immune response, acting as the first im-

type. 23 In EAE, DRmQ increases the binding affinity for the CD74

damage.

3-5

II constructs, namely DRhQ (DRa1L50Q-human (h)MOG-35-55), has

been developed for clinical development11,21 and DRmQ (DRa1L50Q-

12

During stroke pro-

receptor, thereby enhancing the ability of DRa1-mMOG-35-55 to

gression, T cells are also activated,13 serving as a major inflammatory

mune cell-type recruited to the ischaemic area.

competitively inhibit both macrophage migration inhibitory factor

14

Accordingly, targeting any of these

(MIF) and D-dopachrome tautomerase (D-DT) from binding CD74

immune and inflammatory cells may attenuate the secondary cell

and delivering downstream inflammatory effects. 21-22,24 CD74,

trigger to BBB extravasation.

15-19

While promising laboratory stud-

MIF and D-DT are commonly elevated after CNS conditions, such

ies demonstrate effective pharmacological sequestration of stroke

death associated with stroke.

as stroke and EAE. 24 Since DRhQ is the human homolog of DRmQ,

inflammatory cell death by mitigating intrusion of immune and in-

it can circumvent the need for class II tissue typing due to its con-

flammatory cells into the ischaemic penumbra during the acute

served DRα1 moiety, making it ideal for translation to the clinic.11

phase, there exists no robust treatments against the progressive

Following thromboembolic stroke, there is a significant increase

inflammation in the chronic phase. Partial MHC II constructs take

in activated monocytes and neutrophils in the ischaemic cortex, as

advantage of the interplay between central and peripheral inflamma-

well as early activated T cells in the spleen. 20 Previous studies in

tory responses, in which the spleen plays a critical role in modulating

mice with stroke as well as traumatic brain injury have shown that

secondary cell death by manipulating T cell cytokine expression in

partial MHC II inhibitors provide neuroprotection by significantly

both splenic and neurovascular inflammatory pathways. 20-25 In this

attenuating this aberrant immune response in both the central and

review, we discuss preclinical evidence demonstrating that partial

peripheral nervous system.11,20 We advanced the mechanisms by

MHC II constructs pose as potent stroke therapeutics. In particu-

which DRmQ targets both central and peripheral inflammatory re-

lar, that these constructs target both central and peripheral immune

sponses, including the attenuation of splenic inflammation, as ef-

systems represents an innovative treatment strategy for stroke. The

fective means of conferring stroke neuroprotection.11,26 Our recent

|
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study on DRmQ26 represents the first time that this promising ther-

on testing the partial MHC II constructs in the middle cerebral artery

apeutic has been tested in a rat stroke model. Here, we review the

occlusion (MCAo) models, initially testing Dra1-mMOG-35-55 in the

preclinical evidence providing the basic science rationale and trans-

stroke mouse,8,10,20,22-25 and recently evaluating DRmQ in the stroke

lational approach in nurturing the entry of partial MHC II constructs

rat 26 (Table 1). We focus the subsequent sections to DRmQ in our

from the laboratory to clinical application.

efforts to satisfy translational enabling criteria towards clinical application of partial MHC II constructs in stroke.

3 | TE S TI N G D I FFE R E NT PA RTI A L M H C I I
CO N S TRU C T S : FRO M D R α1- h M O G -35 -55
( D R h Q ) To D R a1 L 5 0 Q- m M O G -35 -55 ( D R m Q )

4 | D R m Q TA RG E T S TH E S PLE E N I N
A M E LI O R ATI N G I M M U N E R E S P O N S E I N
S TRO K E M O D E L S

The human homolog of partial MHC II construct is called DRhQ,
while the mouse homolog is DRmQ (Figure 1). DRhQ demonstrated

The PNS and CNS share neuroinflammatory pathways; therefore, it

treatment efficacy by reducing neuroinflammation in multiple ani-

is critical to address both areas of inflammation. 20,26 Poststroke in-

mal models of neurological disorders, including stroke and traumatic

flammation includes a rapid activation of microglia followed by the

brain injury.11 Partial MHC II constructs work as recombinant T cell

infiltration of peripheral inflammatory cells, including neutrophils, T

receptor ligands to competitively bind with CD74 in order to prevent

cells, B cells and macrophages.11 The spleen harbours a number of

it from binding with MIF, thus significantly reducing acute immune

immune cells, and in response to injury upregulates cytokines in the

inflammation response following CNS conditions such as EAE. 22

blood and subsequently the brain after stroke. 27 In a rodent MCAo

Both the MHC and peptide components on these human recombi-

model of stroke, splenocytes are detected in the injured hemisphere

nant T cell receptor ligands (RTLs) are required for treatment effi-

of the brain at 48 and 96 hours. 28 Removing the spleen in mice be-

11

cacy of EAE.

Partial MHC II constructs inhibit acute immune cell

fore stroke significantly reduces lesions, activated macrophages,

entry from the peripheral nervous system in stroke mice, and subse-

microglia and neutrophils in the brain after stroke, thereby further

quently help promote polarization towards an M2 antiinflammation

reinforcing the presence of significant sharing and crosstalk between

phenotype in the CNS.8 Building on this novel therapeutic path-

the PNS and CNS inflammatory pathways.18,29-34 Splenectomy may

way, a new generation of the compound named DRmQ (DRa1L50Q-

be particularly problematic for older patients where immune cells

mMOG-35-55) was created, in which a single amino acid substitution

demonstrate a propensity to work aberrantly and disrupt critical ho-

(L50Q ) in the DRα1 domain strengthens its binding affinity for CD74,

moeostatic pathways related to brain regeneration and repair.35,36

and thus enhancing its antiinflammatory properties. 21 Strong com-

That splenectomy may not work for aged patients solicits finding

petitive inhibition is critical, since studies have shown in mice that

innovative pharmacologic approaches that equally sequester inflam-

stroke induces swift and massive activation of the PNS immune sys-

mation, which may prove more tolerable and effective than a surgi-

tem that subsequently influences and harms the CNS. 20 DRmQ and

cal manoeuvre.

DRhQ effectively treat an EAE mouse model by binding to the cell

Treatment with DRmQ appears to achieve the therapeutic ef-

surface receptor, CD74, that putatively blocks the binding of two in-

fects of splenectomy in that DRmQ reduced the proinflammatory

flammatory factors, MIF and D-DT. 21 Because of the robust inflam-

cytokines interleukin 6 and tumour necrosis factor (TNF)-α in

matory response seen in stroke secondary cell death, we embarked

the spleen. 26 Moreover, DRmQ treated rats exhibit significantly

F I G U R E 1 Partial MHC II Contructs, DRmQ and DRhQ. DR refers to one of the three human leucocyte antigen (HLA) isotypes along
with DP and DQ. The Q refers to a glutamine for lysine amino acid substitution at residue 18 of the DRα1 domain in both constructs. The
“h” and “m” refer to the origin of the antigenic MOG-35-55 peptide: “h” from human MOG and “m” from mouse origin. The C terminus of the
antigenic peptide (in magenta) is covalently linked to the N-terminus of the DRα1 domain through a flexible peptide linker (black). The human
MOG peptide has a proline (P) at position 42, whereas the mouse peptide has a serine (S) at the same position. Structurally, in the DRhQ
molecule, the antigenic peptide is bent due mostly to 2 adjoining proline residues. This might explain the difference in activity of the two
constructs
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TA B L E 1

Milestone stroke studies utilizing DRhQ and DRmQ

Partial MHC II inhibitor

Study

Animal

Significance

DRα1-MOG-35-55
(HLA-DRα1 domain linked to MOG-35-55
peptide)

MCAO Stroke
(Benedek et al, 22 2014)

Mice

Inhibited neuroantigen-specific T cells
Demonstrated binding to CD-74 and inhibiting
MIF.
Reduced symptoms incurred from stroke.
Reversed splenic atrophy after stroke

DRα1-MOG-35-55
(HLA-DRα1 domain linked to MOG-35-55
peptide)

dMCAO Stroke
(Wang et al23, 2017)

Mice

Inhibited neuroantigen-specific T cells
Demonstrated binding to CD-74 and inhibiting
MIF.
Reduced symptoms incurred from stroke.

DRα1-MOG-35-55

Traumatic Brain Injury
(Yang et al24, 2017)

Mice

Significantly reduced CNS inflammation and
improved clinical and histological results after
traumatic brain injury

DRmQ and DRhQ (DRa1L50Q-mMOG-35-55)
and (DRa1L50Q-hMOG-35-55)
More potent versions of partial MHC II
constructs DRα1-MOG-35-55 with single amino
acid substitution (L50Q) in the DRα1 domain

EAE
(Meza-Romero et al21,
2019)

Mice

DRmQ and DRhQ provide stronger binding affinity
for CD-74 receptor.
Better efficacy than DRα1-MOG-35-55 due to
greater inhibition of D-DT and MIF from binding
to CD74 receptor.

DRmQ (DRa1L50Q-mMOG-35-55)
A more potent version of partial MHC II
constructs DRα1-MOG-35-55 with single amino
acid substitution (L50Q) in the DRα1 domain

MCAO Stroke
(Lee et al, 26 2019)

Rats

Provides a second animal model utilizing the
potent next generation partial MHC II construct
inhibitor
This helps fulfil translation into clinic

increased spleen weights. 26 This supports the hypothesis that

CNS following cerebral ischaemia and may cause further damage

DRmQ attenuates the inflammation response in both the PNS and

when left untreated. 39 DRa1-mMOG-35-55 has been also shown

CNS.

26

More importantly, it demonstrates that attenuation of in-

to exert similar therapeutic benefits in the distal MCAo stroke

flammation in the spleen is critical to the pathology and treatment of

model characterized by reducing infarct size, modulating microglia

stroke. Preventing splenic atrophy following stroke has been shown

polarization towards antiinflammatory phenotype and decreasing

to attenuate inflammation and damage in the central nervous system

proinflammatory cytokines such as IL-1α and IL-17. 8,10,11 Microglia,

due to the spleen releasing fewer immune cells to the pathway of

which normally serve as the brain's local macrophages, may dif-

the brain.37 This also implies that DRmQ may be useful in chronic

ferentiate into a proinflammatory M1-like phenotype or antiinflam-

treatment of stroke, in concert with other strategies designed to se-

matory M2-like phenotype. 8,40 However, it should be noted these

quester the deleterious splenic immune response.38,39 That DRmQ

distinct M1-versus-M2 processes have been recently disputed and

affords both CNS and PNS antiinflammatory effect is uniquely im-

are more intricately viewed on a spectrum rather than a binary

portant, because if a partial MHC II construct treats the brain, but

classification.43-45

has no effect on the spleen, then the inflammation incurred by the

Middle cerebral artery occlusion stroke rats treated with DRmQ

spleen may still cause significant damage.8,11 DRmQ’s increased

display significantly reduced expression of TNF-α cytokines and ion-

binding affinity for CD74 makes it vitally more potent in attenuat-

ized calcium binding adaptor molecule-1 (Iba1)-activated microglia

ing both CNS and PNS immune system.11,40 Additionally, while our

and macrophages.26 This may explain the significant attenuation of

studies focused on the spleen, DRmQ may exert additional periph-

secondary inflammation, reduction of infarct size, and increased cell

eral effects that ameliorate stroke-induced impairments beyond

survival demonstrated in this study.18 MCAo stroke rats treated with

dampening the spleen inflammatory response. Indeed, targeting the

DRmQ also exhibit significantly improved motor and neurological

MHC may affect stem cells mobilizing them into the circulation41 or

performances.26

enhancing their differentiation and altering the gut microbiome,

42

altogether potentially fostering therapeutic effects on stroke.

As noted above, our preclinical studies implicate the potential
of DRmQ to exert therapeutic effects in both the CNS and the
PNS, but acknowledged that with construct's enhanced BBB pen-

5 | D R m Q DA M PE N S
N EU RO I N FL A M M ATI O N I N TH E S TRO K E
BR AIN

etration, CNS may be preferentially targeted. In determining the
envisioned clinical dosing regimen, optimizing the timeline of drug
administration and exploring the possibilities to advance DRmQ either as stand-alone or adjunctive treatment to tPA are warranted.
Evaluating its synergistic treatment with tPA and potentially ex-

The expression of Iba1-activated microglia and proinflamma-

panding the therapeutic time window are interesting future trans-

tory cytokine TNF-α are endemic to neuroinflammation in the

lational studies.

|
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these compounds in treating stoke, but more mechanism-based
and translational studies are warranted. 26 While many neurological
disorders are considered as “brain” pathological disorders, there is
also a major peripheral component.8,26,36,37 This would entail that a
holistic approach addressing both the brain and periphery that will

DRmQ, DRhQ and other partial MHC II constructs have the poten-

improve therapeutic outcomes, as opposed to merely targeting the

tial to provide much needed alternative drug treatments that may

brain. This would also support the notion that treating the periphery

extend the therapeutic window for ischaemic stroke, traumatic brain

may promote robust central effects. With these principles in mind,

injury and similar neurodegenerative effects11,25,26 (Figure 2). The

treating splenic inflammation may prove to dampen neuroinflamma-

Stroke Therapy Academic Industry Roundtable (STAIR) criteria have

tion, since many of the circulating inflammatory cells and molecules

been instituted to effectively translate this drug into the clinic.9 At

originate from the spleen, and may likely be sequestered at that level,

least two different species of stroke model are necessary to fully

thereby reducing their influx into the brain.38 Utilizing partial MHC

assess the clinical relevance of partial MHC II constructs. The high-

II constructs may also provide much needed synergistic effects with

lighted study represents the first treatment with partial MHC II con-

current treatments such as tPA, by adding an immune-targeted ther-

struct DRmQ on rats for ischaemic stroke. 26 This is now the second

apeutic modality to attenuate the acute proinflammatory response

animal species in which DRmQ has demonstrated support for treat-

incurred from cerebral ischaemia.8

ment efficacy. Previous studies provided evidence of DRmQ treat11,21

ment efficacy in mice.

It will be essential to perform dose-finding studies to identify

Partial MHC II constructs such as DRhQ

the optimal dosage and potential side effects, as well different

do not require tissue typing due to the conserved DRα1 moiety of

routes of administration and therapeutic window.3,36 Furthermore,

11,21

the drug shared between DRmQ and its human homolog DRhQ.

a longitudinal study will be helpful in ascertaining whether DRmQ

This MHC-independent effect of partial MHC II constructs in con-

has treatment benefits extending into the chronic phase of stroke.

junction with favourable preclinical treatment results in multiple

DRmQ appears to already have a longer time frame of use than cur-

CNS conditions in a variety of species should hasten bringing DRhQ

rent stroke therapies, but a longitudinal study is still needed to see

to clinical trials. 21,26

how long that time frame may be extended.11,26 We did not detect

Our preclinical studies on DRhQ and DRmQ based on animal

any significant harmful histological or behavioural side effects, but

models of stroke provided solid evidence of safety and efficacy of

studies extending into the chronic phase may elucidate detrimental mechanisms or possibly even better therapeutic results. 26 Since
DRmQ was demonstrated to target the spleen, a study focused
on infusing it directly into the spleen may yield beneficial results.
Comparing DRmQ treated stroke rats with or without a splenectomy
may further illuminate how much DRmQ attenuates the peripheral
nervous system's immune response and whether manipulation of
splenic T cells is a key mechanism to its attenuation. Splenectomy
prior to injury has been shown to reduce neuroinflammation and
provide neuroprotection in various brain injury models including
stroke.40 Lastly, it may be helpful to pair DRmQ with other therapies
known to decrease immune inflammation in the spleen and CNS.
To this end, stem cell treatment by administration to the spleen has
been shown to help reduce the immune system's inflammatory response.38,40 Treatment with human bone marrow-derived mesenchymal stem cells that demonstrate homing and antiinflammatory
effects promoted a 40 per cent downregulation of TNF-α in the
spleen.40 Similar antiinflammatory approaches have been tried in
stroke models.46-50 Partial MHC II constructs either as stand-alone
or in combination with these antiinflammatory treatments may
prove as robust stroke therapeutics.
The immune disturbance in stroke has been recognized as a major
exacerbating factor in the secondary cell death in stroke. While the

F I G U R E 2 Therapeutic effects of DRmQ in stroke.
Subcutaneous DRmQ alleviates stroke-induced behavioural
deficits, reduces cerebral infarct volume and peri-infarct cell loss,
lowers stroke-induced inflammatory response in the brain and
attenuates the splenic inflammatory response

secondary cell death entails multiple degenerative processes, the
aberrant immune and inflammatory response appears to produce
the most devastating compromise to the BBB leading to ischaemic
penumbra expansion3-5 The onset of the destructive proinflammatory response is detected as early as a few hours of stroke episode

668
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and remains upregulated even months after stroke onset, thereby
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